PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. Electronic address: dora.buonfrate@sacrocuore.it.\', \'Dipartimento ad attività integrata medico-generale, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.\', \'Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.\', \'Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.\', \'Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.\', \'Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.\', \'Dipartimento di Scienze Biomediche e Cliniche \'Luigi Sacco\', Università degli Studi di Milano, Milan, Italy.\', \'Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.\', \'Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.\', \'Clinical Analysis Laboratory and Transfusional Medicine, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.\', \'Hospital Pharmacy, IRCCS Sacro Cuore-Don Calabria hospital, Negrar di Valpolicella, Verona, Italy.\', \'Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; Department of Diagnostics and Public Health, University of Verona, Verona, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0924-8579(21)01357-110.1016/j.ijantimicag.2021.106516
?:doi
?:hasPublicationType
?:journal
  • International journal of antimicrobial agents
is ?:pmid of
?:pmid
?:pmid
  • 34999239
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.699
?:rankingScore_hIndex
  • 107
is ?:relation_isRelatedTo_publication of
?:title
  • High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34999239>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34999239>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all